Seeking Alpha

The clock is quickly ticking down towards Hemispherx Biopharma's (HEB) Food and Drug Administration (FDA) December 20th meeting with the Arthritis Advisory Committee (AAC) to discuss Ampligen's New Drug Application (NDA) for Chronic Fatigue Syndrome (CFS). As previously announced, the Prescription Drug User Fee Act (PDUFA) review goal for Ampligen is February 2nd, 2013.

The bulls and bears are thus having a vociferous argument over whether or not Ampligen will finally be approved this time around. With about a million people affected by CFS in the U.S. alone, an FDA approval of Ampligen could thus result in one of the more impressive share price appreciations in recent history. Specifically, HEB's current market cap of $116M is several-fold...

Only subscribers can access this article, which is part of the PRO research library covering 3,808 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: